This initiative is part of the brand’s commitment to providing guests with science-backed health and wellness services.

Niagen Bioscience can either commercialise the drug candidate independently or sublicense to a strategic pharmaceutical ...

Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine ...

The buzzy supplement is beloved by celebrities and starting to show up in skin care. But what can it actually do?

Niagen Bioscience Inc. (NASDAQ:NAGE) saw its stock rise 2% after securing an exclusive global commercial license from Norway’s Haukeland University Hospital to develop its nicotinamide riboside ...

Niagen Bioscience (NASDAQ:NAGE) is preparing to release its quarterly earnings on Wednesday, 2025-05-07. Here's a brief overview of what investors should keep in mind before the announcement ...

Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide Outperforming NAD+ IV, Niagen IV (patented nicotinamide riboside or NR) provides ...

Niagen Bioscience, Inc., the global authority on NAD+ with a focus on the science of healthy aging, today announces that senior management will participate at the Roth 15 th Annual London ...

Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook May 07, 2025 4:02 PM ET Niagen Bioscience, Inc. (NAGE) ...

LOS ANGELES (AP) — LOS ANGELES (AP) — Niagen Bioscience, Inc. (NAGE) on Wednesday reported net income of $5.1 million in its first quarter. The Los Angeles-based company said it had net income ...

About Niagen Bioscience: Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a ...